Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs
During the period 1964–1977, regional perfusion and wide local excision were used in the treatment of 104 patients with a locally metastasized malignant melanoma of the limbs. One hundred patients were considered in a study of 3-year and 5-year survival, which was 52% ( 52 100 ) and 38% ( 30 78 ), r...
Gespeichert in:
Veröffentlicht in: | European journal of cancer 1981-04, Vol.17 (4), p.471-476 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | During the period
1964–1977, regional perfusion and wide local excision were used in the treatment of
104 patients with a locally metastasized malignant melanoma of the limbs. One hundred patients were considered in a study of
3-year and
5-year survival, which was
52% (
52
100
) and
38% (
30
78
), respectively. The
3-year and
5-year survival rates in
18 patients treated by normothermic perfusion prior to
1969 were
22% (
4
18
) and
17% (
3
18
), respectively; in
82 patients treated by hyperthermic perfusion after
1969, the
3-year survival was
58.5% (
48
82
) and the
5-year survival was
45% (
27
60
). The difference between the normothermic and hyperthemic group is significant at the
3-year and
5-year level (
P < 0.005 and
P < 0.025, respectively). The
5-year survival in those treated by hyperthermic perfusion was
42% in stage
II (
n = 12) and
46% in stage
III (
n = 48), the difference not being significant. The male
5-year survival was
36% (
8
22
), while the female was
53% (
20
38
). The
5-year survival for tumours of the arm and those of the leg was
23% (
3
13
) and
51% (
24
47
), respectively. No significancy could be demonstrated between these groups. Of the entire group of
100 patients,
35 developed a local recurrence after perfusion; in
11 there was simultaneous general metastazation as well. The recurrence developed within
2 years after perfusion in
27 (77%) patients and
16 (76%) died within
2 years of recurrence. |
---|---|
ISSN: | 0014-2964 |
DOI: | 10.1016/0014-2964(81)90257-7 |